Skip to main navigation
  • About
    • About Vistagen
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
      • Pipeline Overview
    • Fasedienol (PH94B)
      • Fasedienol Overview
      • Social Anxiety Disorder
    • Itruvone (PH10)
      • Itruvone Overview
      • Major Depressive Disorder
    • AV-101
      • AV-101 Overview
    • PH15
      • PH15 Overview
    • Refisolone (PH80)
      • Refisolone Overview
    • PH284
      • PH284 Overview
    • Expanded Access Policy
  • Partnering
  • Publications
    • Fasedienol (PH94B)
    • Itruvone (PH10)
    • Refisolone (PH80)
    • AV-101
  • News & Media
    • Press Releases
    • Videos
    • Media Resources
    • Presentations
  • Investors
    • Investors Overview
      • Company Profile
      • Key Contact Info
      • FAQs
      • Presentations
      • Email Alerts
    • Stock Information
      • Stock Quote & Chart
      • Historical Data
      • Analyst Coverage
    • Press Releases
    • Events
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Results
      • Section 16 Filings
    • Corporate Governance
      • Executive Team
      • Board Committees
      • Documents & Charters
  • Careers
    • Careers
    • Culture
      • Our Purpose
      • Corporate Responsibility
      • Diversity & Inclusion
  • Finding Support
  • Contact
Investors

Investing in innovation to fortify the future of mental health care

Corporate Governance and Nominating Committee

Corporate Governance and Nominating Committee Charter 245.6 KB
Ann Cunningham, MBA Jon S. Saxe, J.D., LL.M
  • Member
  • Chair
  • Financial Expert
  • Independent Director
Key Contact Info Key Contact Info Key Contact Info
FAQ FAQ FAQ
Presentations Presentations Presentations
Email Alerts Email Alerts Email Alerts

Be the first to receive news, events, & updates

Sign-up
Great place to work badge
2025 Platinum Bell Seal for workplace mental health
  • About
    • About Vistagen
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • Fasedienol (PH94B)
    • Itruvone (PH10)
    • AV-101
    • PH15
    • Refisolone (PH80)
    • PH284
    • Expanded Access Policy
  • Publications
    • Fasedienol (PH94B)
    • Itruvone (PH10)
    • Refisolone (PH80)
    • AV-101
  • Contact
  • News & Media
    • Press Releases
    • Videos
    • Media Resources
    • Presentations
  • Investors
    • Investors Overview
    • Stock Information
    • Press Releases
    • Events
    • SEC Filings
    • Corporate Governance
  • Careers
    • Careers
    • Culture
      • Our Purpose
      • Corporate Responsibility
      • Diversity & Inclusion
  • Finding Support
© 2026 Vistagen Therapeutics, Inc. All Rights Reserved.
  • Privacy Policy
  • Disclaimer